Résumé
Objective: To focus attention on the management and outcome of patients with intraductal papillary mucinous tumours of the pancreas.
Design: Retrospective study and analysis of published reports.
Setting: University hospital, France.
Subjects: 111 patients (101 published cases and our own 10 cases) divided in two groups: the first including malignant tumours (n ≥ 46), and the second group benign or in situ tumours (n ≥ 61). In 4 patients the type of tumour was not known.
Main outcome measure: Resectability, mortality and recurrence.
Results: More men had benign or in situ tumours [48/61 (79%) compared with 28/46 (61%), p ≥ 0.054]. Pancreatitis was more common among benign than malignant tumours [34/61 (58%) compared with 21/46 (46%), p ≥ 0.33]. In group I, 39 patients had diabetes. A total of 107 patients were operated on: pancreaticoduodenectomy (n ≥ 54, 50%), distal pancreatectomy (n ≥ 25, 23%), total pancreatectomy (n ≥ 4, 4%), bypass (n ≥ 2, 2%). The type of resection was not mentioned in 22 records (21%). Four patients were not operated on because of their poor general condition. The resectability rate was 98% (105/107). Eleven patients had died at the time of publication. Hospital mortality rate was 3% (n ≥ 3), mainly because 2 of the 4 who had total pancreatectomy died. With a median follow-up of 37 months, recurrence was 5% (n ≥ 5).
Conclusion: Intraductal papillary mucinous tumours of the pancreas are well known distinctive pancreatic tumours that are usually intraductal but may develop into invasive carcinoma. They should be resected, and have a good prognosis and low recurrence rate.